HGH ZPtropin 16 IU

Human Growth Hormone also known as Somatropin, is a polypeptide hormone produced by anterior pituitary gland in brain. It has 191 amino acids and molecular weight of about 22125 Daltons. It is mainly indicated for children who have growth failure due to lack of endogeneous growth. Growth Hormone has significant effects on skeletal growth, carbohydrate metabolism, lipid metabolism, mineral metabolism and connective tissue metabolism. Main functions of growth hormone are that it promotes tissue repair, cell regeneration in bones, and supports immune system in combating infection and disease.

Indications:
Growth Failure
Turner Syndrome
Somatropin Deficiency Syndrome
Small for Gestational Age (SGA)
Idiopathic Short Stature
Prader-Will Syndrome
Adult with AIDS wasting

Usage/Dosage/Administration:
Before injection, slowly dissolve the lyophilized Somatropin powder with 1ml sterile water for injection or bacteriostatic water for injection.

Subcutaneous injection

The recommended dosage of Somatropin is 0.1 IU/kg body weight once daily. It is usually given in the evening before sleep, preferably in the abdominal area. The injection site should change regularly to prevent lipoatrophy.

Contraindications:
Patients with closed epiphysis.

Evidence of tumor activity or active neoplasia (intracranial lesions must be inactive and antitumor therapy completed prior to instituting therapy). Somatropin must be discontinued if there is evidence of tumor activity.

Patients allergic to any component of the product.

There is no clinical experience on the use of somatropin in patients aged more than 60 years.

Adverse Reactions:
Leukemia has occurred in a small number of children receiving Somatropin, although the relationship is uncertain.

Approximately 2% of patients develop antibodies. Of the 232 patients receiving somatropin for 6 months, 4.7% had serum binding of radiolabeled growth hormone in excess of twice the binding observed in control sera.

Somatropin may cause headaches, localized muscle pain, arthralgia, carpal tunnel syndrome, weakness, mild hyperglycemia, and glucosuria. Mild transient edema occurs in 2.5% of patients early during treatment. Local urticarial reactions have rarely been reported at the injection site.

Somatropin may cause infrequent site pain in children. Lipoatrophy has occurred when the site of subcutaneous injection was not varied. This recovers when the injection site is changed. Changes in thyroid hormone laboratory measurements may develop during somatropin treatment in children who lack adequate endogenous growth hormone secretion. Benign intracanial hypertension is a very rare complication of growth hormone therapy.